Skip to main content
Fig. 4 | Journal of Ophthalmic Inflammation and Infection

Fig. 4

From: Interleukin-6 inhibition in the management of non-infectious uveitis and beyond

Fig. 4

A case of an 18-year-old male subject with idiopathic panuveitis and macular edema who was a subject in the STOP-Uveitis Study, demonstrating changes in vitreous haze and central retinal thickness after treatment with intravenous infusions of 4 mg/kg tocilizumab. The subject was not on any other therapy while he was being treated with tocilizumab. [Adapted from Sepah YJ, Sadiq MA, Chu DS, et al. Primary (month-6) outcomes of the STOP-uveitis study: Evaluating the safety, tolerability, and efficacy of tocilizumab in patients with non-infectious uveitis. Am J Ophthalmology 2017; 183:71-80.]

Back to article page